Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer

Summary

This study aims to evaluate the clinical utility of 18F-labeled HER2 Affibody PET for diagnosing and monitoring HER2-expressing breast cancer. HER2, a protein overexpressed in certain malignancies including breast cancer, serves as a critical biomarker for targeted therapies.The HER2 Affibody-an engineered 7 kDa protein with nanomolar affinity for HER2-leverages its rapid tumor penetration and clearance kinetics to achieve high-contrast PET imaging. This study aims to evaluate the diagnostic efficacy of 18F-HER2 Affibody PET in early detection, clinical staging, and treatment response monitoring, thereby providing novel imaging evidence to guide personalized therapeutic strategies for patients with HER2-expressing breast cancer.

Eligibility

Inclusion Criteria:

* Age 18-75 years, ECOG score 0 or 1.
* Clinically or pathologically confirmed diagnosis of patients with HER2 expression breast cancer or suspected expression breast cancer.
* Life expectancy ≥ 12 weeks.
* At least one measurable target lesion according to RECIST 1.1 criteria.
* All participants of reproductive potential (regardless of gender) must commit to using effective contraceptive methods throughout the trial participation and for 6 months after the last PET scan.
* Ability to understand and voluntarily sign the informed consent form, with good compliance.

Exclusion Criteria:

* Severe hepatic or renal dysfunction.
* Pregnant or lactating women, or women planning to become pregnant.
* Inability to lie supine for half an hour.
* Refusal to participate in this clinical study.
* Suffering from claustrophobia or other mental illnesses.
* Other conditions that the investigator deems unsuitable for participation in the trial.

Conditions3

Browse More Trials